A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Inclusion Criteria:

Patients must have documentation of histologically or cytologically confirmed metastatic or locally advanced adenocarcinoma of the distal esophagus, GE junction or stomach
Patients must have documentation of histologically or cytologically confirmed HER2 expression
Patients must be ≥18 years of age
Patients must have ECOG PS of 0, 1, or 2
Patients must have adequate hematologic status, renal and hepatic function

Exclusion Criteria:

Patients with known hypersensitivity to any of the components of MM-111
Patients with a known history of hypersensitivity to paclitaxel or other drugs formulated in Cremophor® EL
Patients with a known history of hypersensitivity to trastuzumab or any of its components (group 1 patients only)
Patients with an active infection or with an unexplained fever >38.5°C